The introduction of all-trans-retinoic acid (ATRA) has significantly improved outcomes for acute promyelocytic leukemia (APL), although a subset of patients still suffer relapse. The purpose of this study was to evaluate the role of maintenance therapy with the synthetic retinoid tamibarotene in APL.
INTRODUCTION
Front-line therapy combining all-trans-retinoic acid (ATRA) and chemotherapy has significantly improved outcomes for patients with acute promyelocytic leukemia (APL). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Nevertheless, up to 30% of patients still experience relapse and die of the disease.
Maintenance therapy is a therapeutic component that potentially reduces the risk of APL relapse. Randomized controlled trials conducted by the North American Intergroup 6 and the European APL Group 11 both demonstrated the beneficial effects of maintenance therapy. In contrast to these studies, we showed that six courses of intensified maintenance chemotherapy did not reduce relapse, but rather worsened overall survival (OS) as a result of higher incidences of late relapse, therapy-related leukemia, and failure to respond to reinduction therapy. 8 More recently, the Gruppo Italiano Malattie Ematologiche dell'Adulto reported that maintenance therapy did not yield any clinical benefits.
14 In view of these conflicting findings, maintenance therapy for APL remains an issue in need of further investigation.
Tamibarotene (formerly Am80) is a synthetic retinoid that induces differentiation of HL-60 and NB-4 cells, with in vitro activity approximately 10 times more potent than that of ATRA. 16, 17 This drug has a low affinity for the cellular retinoic acid binding protein, the overexpression of which is known to be associated with ATRA resistance. 18 In addition, unlike ATRA, tamibarotene has a favorable pharmacokinetic profile because the plasma level does not decline after daily administration. 19 These properties suggest that tamibarotene could be superior to ATRA. We previously conducted a phase II study of tamibarotene in patients with APL who had experienced relapse after ATRA-containing therapy and demonstrated the efficacy and safety of this agent in a relapse setting. 19 These findings prompted the Japan Adult Leukemia Study Group to test tamibarotene as maintenance therapy for APL. To this end, a phase III study, designated APL204, was initiated with the aim of comparing tamibarotene with ATRA as maintenance therapy for patients with newly diagnosed APL. We report here the results of this study.
PATIENTS AND METHODS

Patients
Patients enrolled onto this study had been newly diagnosed with APL with documented cytogenetic and/or molecular evidence of t(15;17)/PML-RARA. Other eligibility criteria included age between 15 and 70 years; an Eastern Cooperative Oncology Group performance status between 0 and 3; and adequate functioning of the liver (serum bilirubin level Ͻ 2.0 mg/L), kidneys (serum creatinine level Ͻ 2.0 mg/dL), lungs (partial pressure of oxygen in arterial blood Ն 60 Torr or saturation of peripheral oxygen Ն 93%), and heart (no severe abnormalities detected on ECG and/or echocardiograms). Written informed consent was obtained from all patients before registration. The protocol was reviewed and approved by the institutional review board of each of the participating centers and was conducted in accordance with the Declaration of Helsinki. This study is registered at the University Hospital Medical Information Network Clinical Trials Registry as C000000154.
Treatments
For remission induction therapy, ATRA was administered to all patients at a daily dose of 45 mg/m 2 until complete remission (CR) or for 60 days, whichever was shorter. The chemotherapy protocol depended on the initial WBC count and blast count in the peripheral blood. If the initial WBC count was less than 3.0 ϫ 10 for 1 day for group C patients. All patients who received additional chemotherapy during the induction course were classified as group D.
Treatment of coagulopathy was risk adapted and stratified into levels 1, 2, and 3. Disseminated intravascular coagulation (DIC) was diagnosed in accordance with the Japanese Ministry of Health and Welfare scoring system.
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Patients with a diagnosis of DIC were treated as level 1 if they met at least one of the following criteria: less than 7 days had elapsed since the start of chemotherapy; complication with retinoic acid syndrome, pneumonia, or severe hemorrhagic complications, or (3) documented increase of the Japanese Ministry of Health and Welfare DIC score. Otherwise, patients with a diagnosis of DIC were treated as level 2, and those without DIC were treated as level 3.
Platelet transfusions were administered to maintain the platelet count greater than 50 ϫ 10 9 /L for level 1, 30 ϫ 10 9 /L for level 2, and 20 ϫ 10 9 /L for level 3. Fresh frozen plasma was transfused to maintain the plasma fibrinogen level greater than 1.5 g/L for level 1, 1.0 g/L for level 2, and as required for level 3. Anticoagulants were used for both levels 1 and 2. Retinoic acid syndrome was treated with high-dose dexamethasone or methylprednisolone along with immediate interruption of ATRA.
Consolidation therapy consisted of three courses of intensive chemotherapy: mitoxantrone 7 mg/m 2 on days 1 to 3 and AraC 200 mg/m 2 on days 1 to 5 for the first course; daunorubicin 50 mg/m 2 on days 1 to 3 and AraC 200 mg/m 2 on days 1 to 5 for the second course; and IDA 12 mg/m 2 on days 1 to 3 and AraC 140 mg/m 2 on days 1 to 5 for the third course. Before the start of the third consolidation course, intrathecal injection of methotrexate, AraC, and prednisolone was used for CNS prophylaxis.
After completion of the third consolidation course, the PML-RARA transcript levels in the bone marrow were assessed. Patients in molecular remission at this time were then randomly assigned to oral administration of ATRA at a daily dose of 45 mg/m 2 or to tamibarotene at a daily dose of 6 mg/m 2 , both for 14 days every 3 months. Random assignment was stratified according to induction treatment (ie, group A, B, C, or D). Maintenance therapy was continued for up to 2 years for a total of up to eight courses.
Assessments
CR was defined as the presence of all of the following: less than 5% of blasts in the bone marrow, no leukemic blasts in the peripheral blood or extramedullary sites, and recovery of peripheral-blood counts. Hematologic relapse was defined as the presence of at least one of the following: recurrence of more than 5% leukemic cells in the bone marrow, recurrence of any leukemic cells in the peripheral blood, or development of extramedullary Abbreviations: ATRA, all-trans-retinoic acid; M3v, M3 variant.
disease. Bone marrow was analyzed for PML-RARA levels after the end of consolidation therapy, after every two courses during maintenance therapy, and every 6 months thereafter. The PML-RARA levels were measured at a single independent laboratory using the real-time quantitative reverse transcription polymerase chain reaction assay as described elsewhere. 8 Levels less than 100 copies/g RNA were defined as molecular remission for this study. If a patient lost molecular remission, an extra bone marrow examination was performed 1 month later to confirm the results. Molecular relapse was defined as loss of molecular remission confirmed in two consecutive bone marrow samples taken 1 month apart.
Statistical Analyses
The primary end point of this study was relapse-free survival (RFS), which was defined as the time from random assignment to hematologic or molecular relapse, death, or last visit, whichever came first. We aimed to include 240 patients in a maintenance random assignment procedure for the detection of an increase in the RFS probability by 17% in the tamibarotene arm compared with the ATRA arm. This sample size ensured two-tailed ␣ ϭ .05, and 1-␤ ϭ .83. All the analyses for maintenance comparisons were intent-totreat analyses.
Distributions of patient characteristics between groups were compared using the Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. The probabilities of RFS and OS were estimated using the Kaplan-Meier method, with differences between groups determined with the log-rank test. OS was defined as the time from registration to death or last visit. The Cox proportional hazards regression model was used for calculating the hazard ratio (HR) in conjunction with the 95% CI. The proportional hazards assumption was tested based on Schoenfeld residuals, 21 and the test for significance showed nonsignificance (P ϭ .491), supporting that the proportional hazard assumption was not violated.
RESULTS
Patients
Between April 2004 and December 2010, 347 patients with newly diagnosed APL were enrolled onto this study. Three patients who had subsequently turned out to be negative for PML-RARA were excluded, leaving 344 patients eligible for analysis. Table 1 lists the baseline characteristics of the eligible patients. 
Excluded from analysis (n = 0)
Excluded from analysis (n = 0) 
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www.jco.org treated as group A, two patients who had been treated as group B, and one patient who had been treated as group C. CR was attained in 319 (93%) of the 344 eligible patients; CR rates by group were as follows: 92% for group A, 91% for group B, 87% for group C, and 99% for group D. Sixteen patients (4.7%) died within 30 days, and 14 of these deaths were associated with hemorrhagic complications. During the median follow-up of 4.3 years (range, 1.3 to 8.0 years), 39 relapses and 37 deaths were documented. The probability of OS for the entire cohort was 89% at 4 years.
Maintenance Comparisons
Among 299 patients who received the third consolidation course, 269 eventually underwent maintenance random assignment; 135 patients were randomly assigned to ATRA, and 134 patients were assigned to tamibarotene. All subsequent comparisons between the two arms were conducted by intention to treat. Table 2 lists the characteristics of randomly assigned patients. The main characteristics were equally distributed between the two arms.
Autologous hematopoietic cell transplantation was performed in 23 patients (16 patients in the ATRA arm and seven in the tamibarotene arm), all after relapse, and allogeneic hematopoietic cell transplantation was performed in two patients (one patient in each arm), both in first CR, for the treatment of secondary myelodysplastic syndrome (MDS). These two patients were censored at the time of transplantation. During the entire follow-up period, 30 patients (20 in the ATRA arm and 10 in the tamibarotene arm) suffered relapse, with the median time from random assignment to relapse of 1.0 year for the ATRA arm and 0.8 year for the tamibarotene arm. Death occurred in two patients in the ATRA arm and four in the tamibarotene arm; the causes of death were transplant-related mortality (n ϭ 2) in the ATRA arm and APL (n ϭ 3) and secondary MDS (n ϭ 1) in the tamibarotene arm. There was only one death during first CR of a patient in the tamibarotene arm 2.1 years after random assignment as a result of MDS. Figure 2 compares the RFS curves of the two arms. RFS rates at 4 years were 84% in the ATRA arm and 91% in the tamibarotene arm, and this difference did not reach statistical significance (P ϭ .095; HR, 0.54; 95% CI, 0.26 to 1.13; Fig 2A) . However, when the analysis was restricted to high-risk patients with an initial WBC count of 10.0 ϫ 10 9 /L or higher, the intergroup difference was statistically significant (P ϭ .028; HR, 0.26; 95% CI, 0.07 to 0.95), with 4-year RFS rates of 58% in the ATRA arm and 87% in the tamibarotene arm (Fig 2B) . For patients whose initial WBC count was lower than 10.0 ϫ 10 9 /L, RFS was almost identical between the arms (90% for the ATRA arm v 92% for the tamibarotene arm; P ϭ .669; HR, 0.82; 95% CI, 0.32 to 2.01; Fig  2C) . The results of a test for interaction between treatment effects and subgroups suggest a possible difference in treatment effects between these two subgroups (P ϭ .075). Table 3 lists grade 2 or higher drug-related adverse events that were reported at a frequency of greater than 5% in either arm. Both treatments were generally well tolerated, and most of the adverse events were grade 2 or lower except for triglyceride increase. Hyperlipidemia was the most common adverse event in both arms, with a higher frequency in the tamibarotene arm. Skin rash was predominantly seen in the tamibarotene arm. Four patients in the ATRA arm and seven in the tamibarotene arm had to discontinue maintenance therapy because of adverse events. In the ATRA arm, nausea (n ϭ 1), headache (n ϭ 1), liver dysfunction (n ϭ 1), and triglyceride increase (n ϭ 1) resulted in discontinuation, whereas skin rash (n ϭ 5), liver dysfunction (n ϭ 1), and coagulopathy (n ϭ 1) resulted in discontinuation in the tamibarotene arm.
DISCUSSION
To the best of our knowledge, this is the first study to evaluate tamibarotene as maintenance therapy for APL. The study results showed no statistical difference between ATRA and tamibarotene, although there was a suggestion of improved efficacy of tamibarotene in high-risk patients in an exploratory analysis.
The role of maintenance therapy in APL has been a matter of controversy. 15 To date, several randomized controlled trials have attempted to address this issue, but with conflicting results. Earlier studies showed significant benefits of maintenance, 6 ,11 whereas more recent studies did not. 8, 14 When discussing the role of maintenance, we should keep in mind that whether and to what extent maintenance therapy provides clinical benefits depends on the target patients. For instance, the addition of effective maintenance therapy may improve outcomes for patients with a certain amount of residual disease, whereas the same does not apply to patients without any residual disease at all when maintenance therapy is started. For this reason, inconsistent or even contradictory results reported by various studies could be explained by differences in types of patients enrolled onto each of these studies. In this regard, it is interesting to note that two studies reporting negative results mainly used IDA for anthracycline drugs, 8, 14 whereas the two studies with positive results used only daunorubicin. 6, 11 In addition, the negative studies used three consolidation courses, 8, 14 but positive studies used only two. 6, 11 These differences indicate that more intensive treatments were used in the former than in the latter studies, which raises the possibility that the more intensive antileukemic effect of the former may have diminished the proportion of patients who actually benefited from maintenance therapy. Also of interest is the fact that only patients with negative PML-RARA at the end of consolidation therapy underwent maintenance random assignment in the two negative studies, 8, 14 whereas all patients with hematologic CR did so, irrespective of minimal residual disease status, in the two positive studies. 6, 11 These conditions may have led to an increase in the percentage of patients in the negative studies who did not actually benefit from maintenance therapy. Therefore, it is not surprising that maintenance random assignment had no impact on outcomes in our non-high-risk patients, because a substantial fraction of these patients may have done well regardless of which maintenance arm they were assigned to, or even without maintenance in some cases, because our study used IDA as well as three courses of consolidation therapy, and only patients whose PML-RARA levels had considerably diminished proceeded to maintenance random assignment.
Our data indicate a possible relationship between the beneficial effects of tamibarotene and the initial WBC count. Patients with an initial WBC count of 10.0 ϫ 10 9 /L or higher are commonly defined as at high risk for relapse. 5, 9 Although statistical significance was not reached, there was a trend for a greater effect size for these high-risk patients. Here we should bear in mind that this subgroup analysis ; random assignment was stratified in terms of induction therapy, which had been decided based on the initial WBC count; and there was a possible difference of treatment effects between the two subgroups. However, this subgroup analysis was not prespecified in the protocol, and the result therefore needs to be interpreted cautiously. Another issue to note is that RFS for high-risk patients in our control arm seems somewhat lower than the RFS rates reported in previous studies using ATRA in combination with continuous chemotherapy, 11,13,14 suggesting the possibility that maintenance therapy with ATRA alone might not be optimal for these patients. The advantage of tamibarotene over ATRA observed in this study thus may have disappeared if these drugs had been combined with continuous chemotherapy. While acknowledging these notions, our data suggest clinical activity of tamibarotene in APL. The fact that this benefit in terms of RFS did not translate into prolonged survival could be largely a result of availability of effective salvage therapy for relapsed APL, because we recently demonstrated the outstanding efficacy of a sequential treatment consisting of induction and consolidation with arsenic trioxide (ATO), peripheral-blood stem-cell harvest after high-dose AraC chemotherapy and autologous hematopoietic cell transplantation for patients with relapsed APL.
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With the accumulation of experience using ATO for relapsed APL, enthusiasm is currently growing for incorporating ATO into front-line therapy in APL clinical trials. [23] [24] [25] [26] Some may argue that this development will irrevocably change the role of maintenance therapy, but prognosis for patients with an initial WBC count of 10.0 ϫ 10 9 /L or higher still seems to remain poor even if they are treated with ATO-containing therapy. 23, 24 For this reason, tamibarotene may play an important role in the ATO era. Moreover, incorporation of tamibarotene along with ATO into front-line therapy for APL may contribute to a reduction in the use of cytotoxic chemotherapy without impairing outcome, which may constitute a major challenge for the future treatment of APL.
In summary, this randomized controlled trial showed no statistical difference between ATRA and tamibarotene for maintenance therapy, but there was a suggestion of improved efficacy of tamibarotene in high-risk patients. This needs to be confirmed in further studies.
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